peer-reviewed publication

Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.

The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.

The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.

The method uses nanopore sequencing to analyze short cell-free DNA fragments from blood, providing results in as little as six hours.

All three methods build on the use of methyltransferases to mark accessible regions of the genome, using nanopore sequencing to detect the modifications.